Decreased serotonin level during pregnancy alters morphological and functional characteristics of tonic nociceptive system in juvenile offspring of the rat.
Serotonin (5-HT) contributes to the prenatal development of the central nervous system, acting as a morphogen in the young embryo and later as a neurotransmitter. This biologically active agent influences both morphological and biochemical differentiation of raphe neurons, which give rise to the descending serotonergic paths that regulate the processing of acutely evoked nociceptive inputs. The involvement of 5-HT in the prenatal development of tonic nociceptive system has not been studied. In the present study we evaluated the effects of a single injection (400 mg/kg, 2 ml, i.p.) of the 5-HT synthesis inhibitor, para-chlorophenylalanine (pCPA), given to pregnant rats during the critical period fetal serotonin development. The functional integrity of the tonic nociceptive response was investigated in 25 day old rats using the classic formalin test. Morphological analysis of brain structures involved in formalin-induced pain and 5-HT levels in the heads of 12-day embryos were also evaluated. Embryonic levels of 5-HT were significantly lowered by the treatment. The juvenile rats from pCPA-treated females showed altered brain morphology and cell differentiation in the developing cortex, hippocampus, raphe nuclei, and substantia nigra. In the formalin test, there were significant decreases in the intensity and duration of the second phase of the formalin-induced response, characterizing persistent, tonic pain. The extent of impairments in the brain structures correlated positively with the level of decrease in the behavioral responses. The data demonstrate the involvement of 5-HT in the prenatal development of the tonic nociceptive system. The decreased tonic component of the behavioral response can be explained by lower activity of the descending excitatory serotonergic system originating in the raphe nuclei, resulting in decreased tonic pain processing organized at the level of the dorsal horn of the spinal cord.
Butkevich
Irina P
IP
Laboratory of Ontogeny of Nervous System, I,P, Pavlov Institute of Physiology, Russian Academy of Sciences, St, Petersburg, Russia. but@kolt.infran.ru
Khozhai
Ludmila I
LI
Mikhailenko
Victor A
VA
Otellin
Vladimir A
VA
D000818:Animals; D001724:Birth Weight / Q000187:drug effects; D001921:Brain / Q000196:embryology; D001923:Brain Chemistry; D004525:Efferent Pathways / Q000196:embryology / Q000503:physiopathology; D005260:Female; D010134:Fenclonine / Q000494:pharmacology / Q000633:toxicity*; D005333:Fetus / Q000737:chemistry / Q000648:ultrastructure; D005865:Gestational Age; D006987:Hypesthesia / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D010147:Pain Measurement; D020671:Posterior Horn Cells / Q000502:physiology; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000097:blood* / Q000187:drug effects; D011297:Prenatal Exposure Delayed Effects; D011903:Raphe Nuclei / Q000196:embryology / Q000503:physiopathology*; D051381:Rats / Q000502:physiology*; D017208:Rats, Wistar; D012701:Serotonin / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D013116:Spinal Cord / Q000196:embryology / Q000503:physiopathology
D012701:Serotonin; D010134:Fenclonine